Rationale and Objective: Recently, interest in the role of aquaporin 1 (AQP1) in human gastrointestinal carcinogenesis has developed. However, to date no studies have examined relationships between AQP1 expression and specific characteristics of gastric adenocarcinoma. Methods: We investigated 109 specimens of primary gastric adenocarcinoma and their corresponding normal gastric mucosa using immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) to determine AQP1 expression. We then evaluated disease free survival (DFS) and overall survival (OS) in these patients in association with AQP1 expression. Results: Both immunohistochemical and RT-PCR analyses identified increased AQP1 expression in tumors from patients with gastric adenocarcinoma (p < 0.001). The 3-year DFS and OS rates were higher in the AQP1-negative group than in the positive group (DFS: 77.2 vs. 52.8%, p < 0.001; OS: 85.1 vs. 70.7%, p < 0.001). The 5-year DFS and OS rates exhibited a similar trend (p < 0.001). Subgroup analysis of patients with early gastric adenocarcinoma (stages I and II) revealed a total 5-year OS of 90.0%, with 5-year OS being higher in the AQP1-negative group than in the positive group (95.2 vs. 84.2%). Furthermore, incidence of tumor recurrence following surgical treatment was significantly higher in the AQP1-positive group (4/19, 21.1%) compared with the negative group (0/21, 0%). Conclusions: Our study demonstrates that AQP1 plays an important role in gastric adenocarcinoma and may therefore represent a novel therapeutic target and prognostic marker in this disease.

Keywords:
Gastric adenocarcinoma, Apoptosis, AQP1
1.
Gao LJ, Gu PQ, Zhao W, Ding WY, Zhao XQ, et al: The role of globular heads of the C1q receptor in HPV 16 E2-induced human cervical squamous carcinoma cell apoptosis is associated with p38 MAPK/JNK activation. J Transl Med 2013;11:118.
2.
Sreedharan S, Petros JA, Master VA, Ogan K, Pattaras JG, et al: Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions. Dis Markers 2014;2014:135649.
3.
Kusayama M, Wada K, Nagata M, Ishimoto S, Takahashi H, et al: Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci 2011;102:1128-1136.
4.
Shimizu H, Shiozaki A, Ichikawa D, Fujiwara H, Konishi H, et al: The expression and role of Aquaporin 5 in esophageal squamous cell carcinoma. J Gastroenterol 2014;49:655-666.
5.
Clapp C, Martínez de la Escalera G: Aquaporin-1: a novel promoter of tumor angiogenesis. Trends Endocrinol Metab 2006;17:1-2.
6.
Nico B, Ribatti D: Aquaporins in tumor growth and angiogenesis. Cancer Lett 2010;294:135-138.
7.
Guo X, Sun T, Yang M, Li Z, Li Z, et al: Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma. Biomed Res Int 2013;2013:206525.
8.
Jiang Y: Aquaporin-1 activity of plasma membrane affects HT20 colon cancer cell migration. IUBMB Life 2009;61:1001-1009.
9.
El Hindy N, Bankfalvi A, Herring A, Adamzik M, Lambertz N, et al: Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma. Anticancer Res 2013;33:609-613.
10.
Hara-Chikuma M, Verkman AS: Aquaporin-3 facilitates epidermal cell migration and proliferation during wound healing. J Mol Med (Berl) 2008;86:221-231.
11.
Skowronska A, Mlotkowska P, Eliszewski M, Nielsen S, Skowronski MT: Expression of aquaporin 1, 5 and 9 in the ovarian follicles of cycling and early pregnant pigs. Physiol Res 2015;64:237-245.
12.
Shen L, Zhu Z, Huang Y, Shu Y, Sun M, et al: Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. Biomed Pharmacother 2010;64:313-318.
13.
Aishima S, Kuroda Y, Nishihara Y, Taguchi K, Iguchi T, et al: Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Hum Pathol 2007;38:1819-1825.
14.
De Luca A, Vassalotti G, Pelagalli A, Pero ME, Squillacioti C, et al: Expression and localization of aquaporin-1 along the intestine of colostrum suckling buffalo calves. Anat Histol Embryol 2015;44:391-400.
15.
Kwon SJ: Evaluation of the 7th UICC TNM staging system of gastric cancer. J Gastric Cancer 2011;11:78-85.
16.
King LS, Agre P: Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996;58:619-648.
17.
Wei M, Shi R, Zeng J, Wang N, Zhou J, et al: The over-expression of aquaporin-1 alters erythroid gene expression in human erythroleukemia K562 cells. Tumour Biol 2015;36:291-302.
18.
Tan M, Shao C, Bishop JA, Feng Z, Trock BJ, et al: Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngol Head Neck Surg 2014;150:801-807.
19.
Chen R, Shi Y, Amiduo R, Tuokan T, Suzuk L: Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China. PLoS One 2014;9:e98576.
20.
Esteva-Font C, Jin BJ, Verkman AS: Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice. FASEB J 2014;28:1446-1453.
21.
Wu Z, Li S, Liu J, Shi Y, Wang J, et al: RNAi-mediated silencing of AQP1 expression inhibited the proliferation, invasion and tumorigenesis of osteosarcoma cells. Cancer Biol Ther 2015;16:1332-1340.
22.
Sun WJ, Lu MD, Yu YJ, Wang FH, Jiang SS, et al: Protein and mRNA expression of aquaporin-1 in gastric tumors and its clinic significance. Chin J General Surg 2010;25:414-415.
23.
Shum H, Rajdev L: Multimodality management of resectable gastric cancer: a review. World J Gastrointest Oncol 2014;6:393-402.
24.
Cho JY: Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer 2013;13:129-135.
25.
Yun P, Zhao XY, Xu M, Fang H, Wang Q, et al: Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One 2014;9:e94536.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.